Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck & Co. Inc. shares rose 1.9% in premarket trade Thursday, after the drug company topped estimates for the first quarter, buoyed by more than $3 billion in sales of its COVID-19 antiviral. The company posted net income of $4.310 billion, or $1.70 a share, for the quarter, up from $2.745 billion, or $1.08 a share, in the year-earlier period.

Merck shares pop premarket after earnings beat as COVID antiviral sales top $3 billion

Merck & Co posted better-than-expected first-quarter earnings and raised its full-year sales estimate on strength from its top-selling cancer drug Keytruda, human papillomavirus (HPV) vaccine Gardasil and its COVID-19 antiviral pill molnupiravir.

Merck quarterly profit tops expectations on demand for COVID pill, cancer drugs

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2022. “We successfully delivered across our key strategic priorities and achieved strong top- and bottom-line growth,” said chief executive officer and president, Robert M. Davis. “Robust first quarter performance was driven by significant clinical advancements in our research pipeline and effective commercial execution across a broa

Merck Announces First-Quarter 2022 Financial Results

AllianceBernstein Hld

Arbor Realty Trust

Ares Capital

BHP Billiton

British American Tobacco

Navient

Pfizer

Philip Morris

Vici Properties

March-April 2022, UBS, Kiplinger, and Barron's analysts/reporters combined to list five-sets of stocks sorted as "inflation busters" for 2022. Those five articles revealed 48 equities, with 43 paying-dividends. Article-titles were, '24 PricingPowerPerformers' [UBS]; '7 REITS Raising-Dividends' [KIP]; '10 Stocks for Rising Interest-Rates' [KIP]; '5 Stocks to Stave-off Sizzling Inflation' [KIP]; '6 Dividend Stocks Whip Inflation' [Barron's].

48 Inflation Busters Feature 8 Ideal Dividend Dogs

Emergent BioSolutions

Gilead Sciences

Eli Lilly

Sanofi

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Merck (MRK)

Not only do we expect Merck to post upbeat Q1 results, but we also find its stock to have more room for growth from its current levels, as we discuss below.

Will Merck Stock Rise After Its Q1 Results?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.

Will Merck (MRK) Beat Expectations This Earnings Season?

AbbVie

Digital Realty Trust

General Mills

Kimberly-Clark

Lockheed Martin

Procter & Gamble

As the population ages, more people are looking for ways to save for retirement. This can be done by investing in retirement stocks.

7 Retirement Stocks to Buy to Sleep Soundly at Night

Amgen

Chevron

Coca-Cola

Visa

Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.

5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA for High-Risk Early-Stage TNBC

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Rising interest rates have caused a tech correction and a rotation into value and quality. MRK is one of 2022's hottest blue-chips, up 14%, the mirror image of the Nasdaq. MRK is up about 20% since December.

Merck Is Still A Strong Buy And Possibly Set To Fly To Record Highs

Intel

Royal Bank of Canada

These are stable businesses that have generous payouts.

3 High-Yielding Dividend Stocks You Can Buy and Forget

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Joseph Romanelli will lead Human Health International, and join Merck's Executive Team, effective August 1, 2022. He will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Arpa Garay leads Human Health Global Marketing, and Jannie Oosthuizen leads Human Health U.S., both also reporting to Davis. “Joe's remarkable t

Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022

Merck & Company (NYSE:MRK) closed last week at a valuation of $86.91. This was after opening the week at $88.32 and touching a high of $89.49.

Here is how to trade Merck as it hovers at the $90 resistance level

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag

Abbott Labs

Johnson & Johnson

Investors who like to follow the movements of hedge funds might be interested in the drug companies that made the list of the top 25 holdings among hedge funds, as reported by Kiplinger.

Big Pharma Favorites of Hedge Funds

Intuitive Surgical

Teladoc

These are the best healthcare stocks to invest in now. ISRG, MRK and TDOC can make great investments in the coming months.

3 Healthcare Stocks That Are Looking Even Healthier

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116

Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company's Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

AstraZeneca

GlaxoSmithKline

Moderna

Do results from an important clinical trial affect the stock price of pharma companies? We're about to find out, as several readouts are expected in the second quarter.

Will These Pharma Giants Pop or Flop on Clinical Study Readouts?

Altria

AT&T

Could dividend stocks be a viable play in the stock market today?

Best Dividend Stocks To Buy Today? 4 In Focus

BioXcel Therapeutics

Tilray Brands

Could health care stocks be the play amidst the current volatility in markets?

Best Stocks To Buy Now? 3 Health Care Stocks For Your List

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, April 28. During the call, company executives will provide an overview of Merck's performance for the quarter and outlook. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast

Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28

Fifth Third Bancorp

NRG Energy

Realty Income Corp

PepsiCo

Phillips 66

Constellation Brands

While the ongoing Russia-Ukraine saga stays in the headlines, what Wall Street is the most focused on is the raging inflation that continues to push higher.

News for Merck Stock (MRK)